2 active not recruiting, 1 recruiting, 1 suspended, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Metastatic Soft-tissue Sarcoma: new trials by email Literature Review of Metastatic Soft-tissue Sarcoma trials Research Report on Metastatic Soft-tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma Zanzalintinib, Ipilimumab, Nivolumab - Metastatic Soft-tissue Sarcoma | Phase 1 | Suspended | Washington University School of Medicine | 18 | 2026-01-05 | 2026-09-04 |
| T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy - Metastatic Soft-tissue Sarcoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 40 | 2025-09-29 | 2026-11-03 |
| HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas Pazopanib, HDM201 - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Centre Leon Berard | 47 | 2022-04-15 | 2026-06-22 |
| A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma NOX66, Doxorubicin - Metastatic Soft-tissue Sarcoma | Phase 1 | Terminated | Noxopharm Limited | 9 | 2022-02-11 | 2025-01-06 |
| Lurbinectedin + Doxorubicin In Leiomyosarcoma Lurbinectedin, Doxorubicin - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Massachusetts General Hospital | 62 | 2022-02-04 | 2026-08-27 |
Sarcoma (5)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Connective and Soft Tissue (5)
Doxorubicin (2) · Cyclophosphamide (1) · Ipilimumab (1) · Nivolumab (1) · PM 01183 (1) · pazopanib (1) · siremadlin (1)
Centre Leon Berard (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Noxopharm Limited (1) · Washington University School of Medicine (1)
United States (4) · France (1)
Gregory Cote, M.D. Ph.D (1) · Mia Weiss, M.D. (1) · Neeta Somaiah, MBBS (1)